Clinical trial

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

NCT04711148

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-03-01

PhasePHASE2

Study timeline

Study start (actual)2021-03-01Date precision: day

Registry last updated2023-04-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing Remitting Multiple Sclerosisunresolved

Interventions

placeboOTHER

orelabrutinibDRUG

Sponsors & collaborators

Beijing InnoCare Pharma Tech Co., Ltd.lead sponsor

Mapped research locations

KharkivUkraine3 BeijingBeijing Municipality, China2 KatowicePoland2 LvivUkraine2 VinnytsiaUkraine2 TampaFlorida, United States1 ShanghaiShanghai Municipality, China1 HangzhouZhejiang, China1 KrakowPoland1 PoznanPoland1 LublinPoland1 ChangshaHunan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04711148 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.